Jaguar8 commented on a stock · Jul 10, 2024 20:34

NEWS

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirmation of PTGR1 as a important biomarker paves the way for further assay validation and eventual use in later-stage clinical trials. Studies have shown that incorporating biomarkers like PTGR1 can significantly enhance clinical trial success rates. LP-184, aimed at treating malignant gliomas, pancreatic cancer, and ATRT, holds both Orphan Drug and Rare Pediatric Disease designations from the FDA.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

7432 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8166

Followers

Following

93K

Visitors